Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting

By Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois, Chloé Chaulet, Jean-Louis Laplanche, Katell Peoc’h, Susanna Schraen, Florence Pasquier, Jacques Touchon, Jacques Hugon, Sylvain Lehmann, Audrey Gabelle Abstract: Background: The assessment of total tau, phosphorylated tau (pTau-181) and amyloid beta (Aβ 1–42) concentrations in the cerebrospinal fluid (CSF) of subjects has been validated for the diagnosis of Alzheimer’s disease (AD). Although these measurements have shown some variability, little is known about their intersite variability in clinical settings.Methods: Read & Research Alzheimer’s More

Leave a Reply